IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other CNS disorders. The company develops Mesdopetam that is in phase IIb clinical studies for the treatment of levodopa-induced dyskinesia; and Pirepemat, which is in phase IIb clinical trial indicated for the treatment of falls frequency, postural dysfunction, cognitive function, and symptoms … Read more
IRLAB Therapeutics AB (publ) (IRLAB-A) - Total Liabilities
Latest total liabilities as of September 2025: Skr116.34 Million SEK
Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) has total liabilities worth Skr116.34 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
IRLAB Therapeutics AB (publ) - Total Liabilities Trend (2013–2024)
This chart illustrates how IRLAB Therapeutics AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
IRLAB Therapeutics AB (publ) Competitors by Total Liabilities
The table below lists competitors of IRLAB Therapeutics AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vertiqal Studios Corp.
PINK:VERTF
|
USA | $14.12 Million |
|
Bicycle Therapeutics Ltd
NASDAQ:BCYC
|
USA | $145.47 Million |
|
Asmallworld AG
SW:ASWN
|
Switzerland | CHF7.32 Million |
|
Almondz Global Securities Limited
NSE:ALMONDZ
|
India | ₹981.50 Million |
|
PT Puri Sentul Permai Tbk
JK:KDTN
|
Indonesia | Rp12.83 Billion |
|
Prashkovsky
TA:PRSK
|
Israel | ILA4.53 Billion |
|
Orgenesis Inc
OTCQB:ORGS
|
USA | $53.62 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down IRLAB Therapeutics AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.22 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IRLAB Therapeutics AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IRLAB Therapeutics AB (publ) (2013–2024)
The table below shows the annual total liabilities of IRLAB Therapeutics AB (publ) from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr103.58 Million | +68.81% |
| 2023-12-31 | Skr61.36 Million | +87.50% |
| 2022-12-31 | Skr32.72 Million | -55.15% |
| 2021-12-31 | Skr72.97 Million | +228.86% |
| 2020-12-31 | Skr22.19 Million | -15.44% |
| 2019-12-31 | Skr26.24 Million | +110.59% |
| 2018-12-31 | Skr12.46 Million | +56.32% |
| 2017-12-31 | Skr7.97 Million | -13.57% |
| 2016-12-31 | Skr9.22 Million | +1.74% |
| 2015-12-31 | Skr9.06 Million | -49.23% |
| 2014-12-31 | Skr17.86 Million | +254971.43% |
| 2013-12-31 | Skr7.00K | -- |